https://biotechmorning.com/news/astellas-stem-cell-seattle-closure Biotech Morning en 2026-04-15T14:07:38.958Z Astellas Paid $102M for a Stem Cell Bet. Now It's Walking Away. https://biotechmorning.com/news/click-therapeutics-layoffs-digital-therapeutics Biotech Morning en 2026-04-15T14:06:56.696Z The App That Treats Schizophrenia Just Lost 27% of Its Team https://biotechmorning.com/news/fda-clinical-trial-reporting-crackdown-2026 Biotech Morning en 2026-04-15T14:06:14.675Z The FDA Just Sent 2,200 Companies a Very Uncomfortable Reminder https://biotechmorning.com/news/senator-sasse-pancreatic-cancer-revolution-medicines-trial Biotech Morning en 2026-04-15T14:05:30.919Z The Senator Who Bet His Life on a Drug That Didn't Exist Two Years Ago https://biotechmorning.com/news/neomorph-100m-molecular-glue-degrader Biotech Morning en 2026-04-14T14:13:46.875Z The $100M Bet on Drugs That Work Like Superglue https://biotechmorning.com/news/kailera-therapeutics-ipo-obesity-drugs Biotech Morning en 2026-04-14T14:13:05.406Z The $528M Bet That Obesity Drugs Still Have Room for One More https://biotechmorning.com/news/big-pharma-immunology-spring-cleaning-2 Biotech Morning en 2026-04-14T14:12:20.806Z Big Pharma's Immunology Spring Cleaning Has Begun https://biotechmorning.com/news/alamar-biosciences-ipo-billion-dollar-valuation Biotech Morning en 2026-04-14T14:11:35.666Z The Protein Company That Tripled Revenue Wants a Billion-Dollar Valuation https://biotechmorning.com/news/abbvie-745m-haisco-pain-deal Biotech Morning en 2026-04-14T14:10:50.119Z AbbVie's $745M Bet That Pain Relief Doesn't Need Opioids https://biotechmorning.com/news/lilly-300m-crossbridge-bio-adc-acquisition Biotech Morning en 2026-04-14T14:10:05.057Z Lilly's $300M Bet on a Biotech That Doesn't Even Have a Drug in Humans Yet